Collegium Pharmaceutical (COLL) Projected to Release Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $1.68 per share and revenue of $199.6250 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The business had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business posted $1.49 earnings per share. On average, analysts expect Collegium Pharmaceutical to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $35.73 on Wednesday. The company has a fifty day moving average price of $34.91 and a 200 day moving average price of $37.32. The firm has a market cap of $1.16 billion, a PE ratio of 17.51 and a beta of 0.73. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical has a 1-year low of $29.70 and a 1-year high of $50.79.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently bought and sold shares of the company. Group One Trading LLC acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Kemnay Advisory Services Inc. acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at $61,000. EverSource Wealth Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Collegium Pharmaceutical by 225.3% during the 4th quarter. Federated Hermes Inc. now owns 2,837 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 1,965 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 304.6% during the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 2,294 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.